FDA Grants Fast Track Designation to Oncoprex Combination for NSCLC |
Oncoprex in combination with osimertinib received fast track designation from the FDA to treat patients with non-small cell lung cancer. |
Read more
|
|
ICYMI: Improved QOL Observed in Patients with CRC Treated with Triplet and Doublet Regimen |
The patients with BRAF V600E-mutant metastatic colorectal cancer whose disease had progressed after 1 or 2 prior regimens reported substantial improvements in quality of life over the current standard of care. |
Read more
|